OTLC · Oncotelic Therapeutics, Inc.

On July 10, 2026, the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

On July 10, 2026, the reporting person was granted 250 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

On July 10, 2026, the reporting person was granted 2,000 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

On July 10, 2026, the reporting person was granted 1,500 restricted stock units ("RSUs"), subject to performance and time-based vesting. On vesting each RSU will immediately be settled by delivery of, and each RSU represents the contingent right to receive, one share of the issuer's Series A Convertible Preferred Stock, par value $0.01. Each share of Series A Convertible Preferred Stock, in turn, is convertible into 1,000 shares of the issuer's common stock, par value $0.01 per share.

The RSU's will vest upon (a) achievement of an uplisting of the issuer's common stock to a national securities exchange on or before June 30, 2027 (or such later date as the Board of Directors may approve), subject to the reporting person's continued service for a period of six months following the uplisting.

On July 1, 2026, Dr. Vuong Trieu purchased 240,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0431.

On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045.

On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045.

On June 22, 2026, Amit Shah purchased 20,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05.

On June 22, 2026, Dr. Vuong Trieu purchased 65,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 23, 2026, Dr. Vuong Trieu purchased 75,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045. Further, on June 24, 2026, Dr. Vuong Trieu purchased 115,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.045.

On June 15, 2026, Dr. Vuong Trieu purchased 96,000 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.05. Further, on June 17, 2026, Dr. Vuong Trieu purchased 239,759 shares of Oncotelic Therapeutics, Inc. in his individual capacity, from the open market at a price of $0.0446.

Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis.

The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated January 21, 2026.

Series A Convertible Preferred Stock is convertible at any time at the option of the holder into Common Stock on a one-for-one thousand basis.

The shares of Series A Convertible Preferred Stock were issued to Dr. Trieu as compensation pursuant to the accomplishment of performance milestones under a Restricted Stock Agreement dated November 17, 2025.

Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022.

Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022.

Stock Options vest as follows: (i) 50% of the options will vest upon the consummation of a qualifying joint venture agreement, licensing agreement, or acquisition transaction (a "Corporate Transaction"); (ii) The remaining 50% on the one-year anniversary of the consummation of a Corporate Transaction.

Stock options vest as follows: (i) 1/5th on September 30, 2021; (ii) 1/5th on December 31, 2021; (iii) 1/5th on March 31, 2022; (iv) 1/5th on June 30, 2022; and (v) 1/5th on September 30, 2022.

Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan and which vest immediately on the date of grant.

Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.

Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on date of grant.

Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant.

Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.

Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant.

Shares were issued in settlement of Restricted Stock Units granted pursuant to the Issuer's 2015 Equity Incentive Plan that vested immediately upon grant.

Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vests immediately on the date of grant.

Stock options granted pursuant to the Issuer's 2015 Equity Incentive Plan, which vest immediately on the date of grant.

Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.

Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the "Merger"), shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.

Shares of the Series A Convertible Preferred Stock does not expire.

Pursuant to the Agreement and Plan of Merger dated April 17, 2019, between the Issuer and Oncotelic, Inc., shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.

Shares of the Series A Convertible Preferred Stock does not expire.

Pursuant to the Agreement and Plan of Merger dated August 17, 2019, as amended November 1, 2019, between the Issuer and PointR Data Inc., (the "Merger"), shares of the Issuer's Series A Convertible Preferred Stock ("Series A Preferred") held by the reporting person converted into shares of the Issuer's common stock, following a recapitalization by the Issuer.